STOK
Stoke Therapeutics, Inc.Healthcare·Biotechnology
$30.91
$1.9B market cap
Revenue
$7.6M
Free Cash Flow
$-91.6M
Rev Growth
+0.0%
FCF Margin
-1200.6%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and ST
2-Year Price History
$29.34+100.7%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 6.2 | -52.4 | -53.4 | -50.0 | -60.6 | -60.9 | -0.4 | 343.6 | 3.4 | 63.1 | -134.7% | -15.4x | -- |
| Act | 2025-Q4 | 1.4 | -60.4 | -61.4 | -57.9 | -30.5 | -30.7 | -0.2 | 284.7 | 0.0 | 58.4 | -214.6% | -20128.0x | -- |
Valuation & Metrics
Market Stats
Price$30.91
Market Cap$1.9B
Enterprise Value$1.6B
P/S Ratio252.3x
P/FCF--
EV/FCF--
FCF Margin (TTM)-1200.6%
FCF Yield-4.8%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$7.6M
Net Income$-107.9M
Free Cash Flow$-91.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin-1477.6%
Net Margin-1414.5%
FCF Margin-1200.6%
CapEx % of Revenue7.7%
SBC % of Revenue243.8%
ROIC-174.7%
WC Change % Rev48.0%
Interest Coverage-33.2x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares13.0M
Days to Cover27.0
Change (vs Prior)+3.9%
Need at least 2 settlement dates for chart
Employees
Headcount128
Revenue / Employee$59,617
Gross Profit / Employee$43,195
Cash Runway
45.0months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
99.9%(+81.7% YoY)
179 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
23.9%(+19.5% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.5%(+0.5% YoY)
6 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | $183M | $15.23 | +$2.5M | +$16.3M | -2.3% | $9.26B |
| BlackRock, Inc.Passive | $175M | $12.90 | +$5.6M | −$15.5M | -0.2% | $5.69T |
| FMR LLC | $175M | $10.17 | −$7.1M | +$92.5M | -0.0% | $1.89T |
| Lynx1 Capital Management LP | $155M | $8.40 | −$20.9M | −$17.2M | -0.1% | $633M |
| Redmile Group, LLC | $136M | $10.93 | +$4.2M | −$10.5M | -6.1% | $1.51B |
| MORGAN STANLEY | $111M | $10.35 | −$4.0M | −$5.5M | -0.3% | $1.65T |
| BAKER BROS. ADVISORS LP | $109M | $10.89 | +$0 | −$42.2M | -0.5% | $16.13B |
| TORONTO DOMINION BANK | $103M | $11.03 | +$0 | +$0 | -0.3% | $51.69B |
| WELLINGTON MANAGEMENT GROUP LLP | $101M | $30.23 | +$76.8M | +$96.4M | -0.3% | $533.98B |
| BVF INC/IL | $82.9M | $26.47 | +$9.2M | +$82.9M | -0.4% | $3.14B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $76.7M | $32.56 | +$76.7M | +$76.7M | — | $4.04T |
| STATE STREET CORPPassive | $74.1M | $21.07 | −$7.2M | +$22.8M | -0.2% | $2.89T |
| Siren, L.L.C. | $65.0M | $10.55 | −$8.2M | −$8.2M | +5.9% | $3.61B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $63.0M | $32.23 | +$50.9M | +$61.7M | -0.2% | $864.93B |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $59.4M | $31.74 | +$0 | +$59.4M | -0.8% | $7.18B |
| JANUS HENDERSON GROUP PLC | $52.5M | $30.19 | +$5.3M | +$51.8M | +1.2% | $209.29B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $43.1M | $17.94 | +$5.1M | +$13.7M | +2.3% | $1.61T |
| Polar Capital Holdings Plc | $36.9M | $15.39 | −$4.4M | +$36.9M | +1.5% | $22.76B |
| DIMENSIONAL FUND ADVISORS LPPassive | $32.2M | $17.34 | +$5.3M | +$10.6M | -0.4% | $480.92B |
| Assenagon Asset Management S.A. | $29.5M | $17.83 | −$10.4M | −$1.7M | +0.1% | $62.57B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.39%
avg per quarter
Holders (ex-self)
-0.69%
excl. this stock
Buyers (this Q)
-0.57%
120 buyers · $0.41B in
Sellers (this Q)
+1.33%
54 sellers · $0.08B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-21.6%
how holders react when this stock falls
On quiet Qs
+4.7%
−10% to +10% baseline
On rallies (+10%+)
+2.4%
how they react when this stock rises
Holders' portfolio flow this Q
+8.6%
inflows — adds are organic
Sellers' portfolio flow this Q
+3.2%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.1%
Holder mid (any stock)
-3.5%
Holder rally (any stock)
-1.3%
Biggest decreases this quarter
Point72 Asset Management, L.P.exited−$38.8MLynx1 Capital Management LP−$20.9Mα-0.1Assenagon Asset Management S.A.−$10.4Mα+0.1GOLDMAN SACHS GROUP INC−$10.2Mα-0.2Siren, L.L.C.−$8.2Mα+5.9STATE STREET CORP−$7.2Mα-0.2FMR LLC−$7.1Mα-0.0Polar Capital Holdings Plc−$4.4Mα+1.5MORGAN STANLEY−$4.0Mα-0.3Penserra Capital Management LLCexited−$2.8M
New buyers this quarter
Top-5 holders · 35.6%
RTW INVESTMENTS, LP--
BlackRock, Inc.--
FMR LLC--
Lynx1 Capital Management LP--
Redmile Group, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Skorpios Trust—RTW INVESTMENTS, LP5.6MFMR LLC5.4MLynx1 Capital Management LP4.8MRedmile Group, LLC4.2MMORGAN STANLEY3.4MBAKER BROS. ADVISORS LP3.3MTORONTO DOMINION BANK3.2MWELLINGTON MANAGEMENT GROUP LLP3.1MBVF INC/IL2.5M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$40.002940.0%
Last Year (10 analysts)$39.802880.0%
Current Price$30.91
Analyst Ratings
12
3
Buy: 12Hold: 3Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$4.90M
27 txns · 8 insiders · 142,553 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | SELL | Ticho Barry | officer: CHIEF MEDICAL OFFICER | 2,243 | $32.79 | $74K | $1.20M |
| 2026-04-01 | SELL | Ticho Barry | officer: CHIEF MEDICAL OFFICER | 1,838 | $32.66 | $60K | $1.27M |
| 2026-03-20 | SELL | Allan Jonathan | officer: GENERAL COUNSEL & CORP SEC | 9,293 | $33.69 | $313K | $658K |
| 2026-03-19 | SELL | Ticho Barry | officer: CHIEF MEDICAL OFFICER | 1,461 | $29.99 | $44K | $1.22M |
| 2026-03-18 | SELL | Allan Jonathan | officer: GENERAL COUNSEL & CORP SEC | 4,628 | $31.34 | $145K | $904K |
| 2026-03-18 | SELL | Hoitt Jason | officer: Chief Patient Officer | 1,931 | $31.34 | $61K | $322K |
| 2026-03-18 | SELL | Leggett Thomas | officer: Chief Financial Officer | 2,382 | $31.34 | $75K | $319K |
| 2026-03-18 | SELL | Ticho Barry | officer: CHIEF MEDICAL OFFICER | 6,686 | $31.34 | $210K | $1.28M |
| 2026-03-17 | SELL | Allan Jonathan | officer: GENERAL COUNSEL & CORP SEC | 4,267 | $33.01 | $141K | $1.10M |
| 2026-03-17 | SELL | Hoitt Jason | officer: Chief Patient Officer | 1,781 | $33.01 | $59K | $403K |
| 2026-03-17 | SELL | Leggett Thomas | officer: Chief Financial Officer | 2,196 | $33.01 | $72K | $414K |
| 2026-03-17 | SELL | Ticho Barry | officer: CHIEF MEDICAL OFFICER | 6,164 | $33.01 | $203K | $1.57M |
| 2026-03-13 | SELL | LEVIN ARTHUR A | director | 605 | $36.80 | $22K | $156K |
| 2026-03-10 | SELL | TZIANABOS ARTHUR | director, officer: Interim Executive Chair | 4,355 | $40.00 | $174K | $1.25M |
| 2026-03-10 | SELL | Krainer Adrian R. | director | 33,243 | $39.74 | $1.32M | $11.26M |
| 2026-03-02 | SELL | Krainer Adrian R. | director | 7,229 | $39.66 | $287K | $12.55M |
| 2025-12-08 | SELL | Allan Jonathan | officer: GENERAL COUNSEL & CORP SEC | 3,978 | $32.28 | $128K | $382K |
| 2025-12-08 | SELL | Kaye Edward M. MD | director | 13,430 | $32.27 | $433K | $1.59M |
| 2025-12-05 | SELL | Allan Jonathan | officer: GENERAL COUNSEL & CORP SEC | 8,785 | $31.29 | $275K | $495K |
| 2025-12-05 | SELL | Kaye Edward M. MD | director | 8,548 | $31.32 | $268K | $1.96M |
Order Flow (FINRA, ~3w lag)
13.4%retail+4.3pp
21.9%dark-0.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Stoke Therapeutics: Biogen Windfall Masks Escalating Operating Burn and Significant Partner Attrition
Overall Risk
6/10
Fraud
3/10
Dilution
8/10
Insolvency
3/10
Earnings Overstated
7/10
Hidden Liabilities
4/10
Legal
3/10
Audit Warnings
2/10
Hidden Upside
5/10
Contextually Acceptable
7/10